menu
    • menu

    Company profile for Addex Therapeutics

    NEW Drugs in Dev: 4
    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    Nanjing Well is focused on R&D, production & sales of Pharmaceutical Excipients & Synthetic Lubricating base oils.

    Virtual Booth

    Contact Supplier

    Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances, suspensions, etc.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs.Addex's allosteric modulator drug...
    Addex Therapeutics is a biopharmaceutical company focused on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. Allosteric modulators are an emerging class of small molecule drugs which have the potential to be more specific and confer significant therapeutic advantages over conventional "orthosteric" small molecule or biological drugs.Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention - the Addex pipeline was generated from this pioneering allosteric modulator drug discovery platform.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Addex TherapeuticsSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    12, chemin des Aulx, Case postale 68, 1228 Plan-les-Ouates, Geneva
    Telephone
    Telephone
    +41 22 884 1555
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.addextherapeutics.com/en/
    Linkedin
    Linkedin
    https://in.linkedin.com/company/addex-therapeutics
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Addex GABAB PAM Shows Anti-Tussive Activity in IPF Model
    Addex GABAB PAM Shows Anti-Tussive Activity in IPF Model

    29 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/29/3283424/0/en/addex-gabab-pam-candidate-demonstrates-solid-anti-tussive-activity-in-bleomycin-ipf-related-chronic-cough-model.html

    GLOBENEWSWIRE
    29 Apr 2026
    Share Share
    Neurosterix Advances NTX-253 For Schizophrenia Phase 1 Study
    Neurosterix Advances NTX-253 For Schizophrenia Phase 1 Study

    23 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/23/3279552/0/en/addex-spin-out-company-neurosterix-on-track-to-complete-phase-1-clinical-study-of-ntx-253-for-schizophrenia-in-q2-2026.html

    GLOBENEWSWIRE
    23 Apr 2026
    Share Share
    Addex Publishes Preclinical Data On mGlu7 NAMS For Anxiety
    Addex Publishes Preclinical Data On mGlu7 NAMS For Anxiety

    03 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/03/3230712/0/en/Addex-Announces-Publication-of-Preclinical-Data-Supporting-Potential-of-mGlu7-Negative-Allosteric-Modulators-to-Transform-Anxiety-and-Fear-Related-Disorder-Treatment.html

    GLOBENEWSWIRE
    03 Feb 2026
    Share Share
    Neurosterix Launches Phase 1 Study of NTX-253 in Schizophrenia
    Neurosterix Launches Phase 1 Study of NTX-253 in Schizophrenia

    07 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/07/3214260/0/en/Addex-Spin-Out-Neurosterix-has-started-a-Phase-1-Clinical-Study-with-M4-PAM-NTX-253-for-Schizophrenia.html

    GLOBENEWSWIRE
    07 Jan 2026
    Share Share
    Addex Amends Market Agreement With H.C. Wainwright & Co.
    Addex Amends Market Agreement With H.C. Wainwright & Co.

    11 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/11/3203606/0/en/Addex-Amends-its-at-the-Market-Offering-Agreement-With-H-C-Wainwright-Co.html

    GLOBENEWSWIRE
    11 Dec 2025
    Share Share
    Addex Therapeutics Reports Q3 2025 Results and Corporate Update
    Addex Therapeutics Reports Q3 2025 Results and Corporate Update

    04 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/04/3199484/0/en/Addex-Therapeutics-Reports-2025-Third-Quarter-Financial-Results-and-Provides-Corporate-Update.html

    GLOBENEWSWIRE
    04 Dec 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search